Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations
Macromolecular versus small-molecule therapeutics: Drug discovery, development and clinical considerations
复制标题
DOI：
10.1016/0167-7799(96)10024-x
复制
发表时间：
1996-05-01
影响因子：
17.3
通讯作者：
Juliano, R
中科院分区：
文献类型：
--
作者：
Cho, MJ;Juliano, R
生物医学科学的最新进展，特别是分子生物学，在分子和（亚）细胞水平上提供了更好的理解发病机制。反过来，这又刺激了大分子、基于机制的治疗剂的开发，范围从重组蛋白到寡核苷酸到基因/基因片段。成功开发这类新的治疗剂所必需的因素不一定与开发常规小有机分子所必需的因素相同。本文综述了大分子药物开发中的几个问题，并强调了药物转运和递送的关键问题。
Recent advances in biomedical science in general, and molecular biology in particular, have provided a greater understanding of pathogenesis at the molecular and (sub)cellular level. In turn, this has stimulated the development of macromolecular, mechanism-based therapeutic agents, ranging from recombinant proteins, to oligonucleotides, to genes/gene fragments, The factors essential for the successful development of this new class of therapeutic agents are not necessarily the same as those for the development of conventional small organic molecules. This review mentions several issues relating to the development of macromolecular drugs, and emphasizes the key issue of drug transport and delivery.